COHANCE LIFESCIENCES LTD COHANCE NIFTY_SMALLNSEPHARMA
Company Overview
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Why Investors Should Care
Revenue has grown at a 19.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.10.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹2,268.55 Cr (-13.0% YoY); net profit ₹179.23 Cr.
- Trailing 12 Months Year-on-year growth — revenue -13.0%, earnings -63.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.4%, profit CAGR -24.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.45% |
| 1 Year: | -13.03% |
Compounded Profit Growth
| 5 Years: | -24.19% |
| 1 Year: | -63.22% |
Stock Price Performance
| 1 Year: | -55.90% |
| 6 Months: | -3.98% |
| 3 Months: | +12.46% |
| 1 Month: | +1.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.16 · Neutral
P/E of 93.85 is above the sector median of 39.97 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 19.4% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 93.8.
- Earnings shrank at -24.2% CAGR over 5 years.
- Trading 60.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COHANCE COHANCE LIFESCIENCES LTD NIFTY_SMALLNSEPHARMA | 439.20 | 93.85 | ₹16,802.35 Cr | 0.00% | 4.81% | 4.58% | 19.45% | -24.19% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 369.36 Cr | 347.55 Cr | 231.05 Cr | 219.82 Cr | 252.93 Cr | 488.08 Cr | 603.77 Cr | - | 840.42 Cr | 549.31 Cr | 555.57 Cr | 544.55 Cr | 619.12 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 300.02 Cr | 148.14 Cr | 141.13 Cr | 158.91 Cr | 214.45 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 540.40 Cr | 401.17 Cr | 414.44 Cr | 385.64 Cr | 404.67 Cr |
| Operating Expenses | 197.50 Cr | 180.59 Cr | 133.09 Cr | 153.74 Cr | 179.58 Cr | 362.98 Cr | 398.40 Cr | - | 365.35 Cr | 334.30 Cr | 337.51 Cr | 337.23 Cr | 357.22 Cr |
| Operating Income | 159.84 Cr | 154.42 Cr | 86.07 Cr | 53.29 Cr | 56.10 Cr | 93.82 Cr | 167.58 Cr | - | 175.05 Cr | 66.87 Cr | 76.93 Cr | 48.41 Cr | 47.45 Cr |
| EBITDA | 171.86 Cr | 166.96 Cr | 97.96 Cr | 66.08 Cr | 73.35 Cr | 125.10 Cr | 205.37 Cr | - | 225.49 Cr | 118.08 Cr | 136.55 Cr | 96.65 Cr | 80.33 Cr |
| Interest Expense | 5.03 Cr | 1.15 Cr | 50.00 L | 2.16 Cr | 2.30 Cr | 10.20 Cr | 9.61 Cr | - | 10.45 Cr | 10.18 Cr | 8.76 Cr | 9.11 Cr | 9.19 Cr |
| Pretax Income | 166.21 Cr | 163.94 Cr | 105.41 Cr | 65.47 Cr | 70.85 Cr | 103.03 Cr | 174.16 Cr | - | 160.87 Cr | 62.76 Cr | 83.77 Cr | 40.60 Cr | 19.91 Cr |
| Tax Provision | 42.23 Cr | 43.35 Cr | 25.84 Cr | 18.72 Cr | 17.48 Cr | 27.66 Cr | 35.91 Cr | - | 43.72 Cr | 16.36 Cr | 17.38 Cr | 11.58 Cr | 11.60 Cr |
| Net Income | 123.97 Cr | 120.59 Cr | 79.56 Cr | 46.75 Cr | 53.37 Cr | 75.37 Cr | 138.24 Cr | - | 120.43 Cr | 48.82 Cr | 74.08 Cr | 36.72 Cr | 19.55 Cr |
| Diluted EPS | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 2.96 | 5.44 | - | 3.10 | 1.27 | 1.92 | 0.96 | 0.50 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 378.00 Cr | 834.00 Cr | 1,010.00 Cr | - | 1,331.11 Cr | 1,034.06 Cr | 2,608.50 Cr | 2,268.55 Cr |
| Cost of Revenue | - | - | - | - | 586.19 Cr | 317.85 Cr | 816.48 Cr | 662.63 Cr |
| Gross Profit | - | - | - | - | 744.92 Cr | 716.21 Cr | 1,792.02 Cr | 1,605.92 Cr |
| Operating Expenses | 206.00 Cr | 449.00 Cr | 567.00 Cr | - | 218.61 Cr | 361.81 Cr | 1,161.76 Cr | 1,366.26 Cr |
| Operating Income | 160.00 Cr | 361.00 Cr | 411.00 Cr | - | 526.30 Cr | 354.40 Cr | 630.26 Cr | 239.66 Cr |
| EBITDA | 172.00 Cr | 385.00 Cr | 443.00 Cr | - | 620.53 Cr | 467.22 Cr | 850.49 Cr | 431.61 Cr |
| Interest Expense | 3.00 Cr | 23.00 Cr | 12.00 Cr | - | 12.81 Cr | 6.95 Cr | 41.06 Cr | 37.24 Cr |
| Pretax Income | 158.00 Cr | 405.00 Cr | 468.00 Cr | - | 559.73 Cr | 405.67 Cr | 642.63 Cr | 207.04 Cr |
| Tax Provision | 48.98 Cr | 89.10 Cr | 107.64 Cr | - | 148.44 Cr | 105.39 Cr | 158.39 Cr | 56.92 Cr |
| Net Income | 109.00 Cr | 317.00 Cr | 362.00 Cr | - | 411.29 Cr | 300.28 Cr | 487.34 Cr | 179.23 Cr |
| Diluted EPS | - | 12.45 | 14.23 | - | 16.16 | 11.80 | 12.68 | 4.68 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 783.00 Cr | 1,173.00 Cr | 1,474.00 Cr | - | 1,965.74 Cr | 2,254.91 Cr | 3,031.75 Cr | 5,729.64 Cr |
| Current Assets | - | - | - | - | 1,011.05 Cr | 1,252.78 Cr | 888.59 Cr | 1,827.96 Cr |
| Cash & Equivalents | - | - | - | - | 64.80 Cr | 47.23 Cr | 85.40 Cr | 49.14 Cr |
| Inventory | - | - | - | - | 312.81 Cr | 231.20 Cr | 166.57 Cr | 562.23 Cr |
| Receivables | - | - | - | - | 110.94 Cr | 133.66 Cr | 284.44 Cr | 681.01 Cr |
| Total Liabilities | - | - | - | - | 230.56 Cr | 204.24 Cr | 1,191.11 Cr | 1,695.81 Cr |
| Current Liabilities | - | - | - | - | 158.77 Cr | 117.40 Cr | 365.19 Cr | 645.93 Cr |
| Long Term Debt | - | - | - | - | 4.56 Cr | 0 | 6.24 Cr | 50.48 Cr |
| Total Debt | 83.00 Cr | 186.00 Cr | 143.00 Cr | - | 70.34 Cr | 65.01 Cr | 279.07 Cr | 400.49 Cr |
| Total Equity | 578.00 Cr | 845.00 Cr | 1,180.00 Cr | - | 1,735.18 Cr | 2,050.67 Cr | 1,696.58 Cr | 3,911.29 Cr |
| Shares Outstanding | - | - | - | - | 25.46 Cr | 25.46 Cr | 25.46 Cr | 38.26 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 50.00 Cr | 407.00 Cr | 383.00 Cr | - | 457.20 Cr | 384.77 Cr | 673.35 Cr | 368.32 Cr |
| Investing Cash Flow | -65.00 Cr | -413.00 Cr | -311.00 Cr | - | -195.01 Cr | -362.35 Cr | -389.70 Cr | -254.57 Cr |
| Financing Cash Flow | 26.00 Cr | 7.00 Cr | -76.00 Cr | - | -241.95 Cr | -39.99 Cr | -327.40 Cr | -165.15 Cr |
| Capital Expenditure | -56.00 Cr | -103.00 Cr | -111.00 Cr | - | -285.91 Cr | -51.88 Cr | -316.80 Cr | -219.88 Cr |
| Free Cash Flow | -6.00 Cr | 304.00 Cr | 272.00 Cr | - | 171.28 Cr | 332.89 Cr | 356.55 Cr | 148.44 Cr |
| Net Change in Cash | 11.00 Cr | 1.00 Cr | -5.00 Cr | - | 20.24 Cr | -17.57 Cr | -43.75 Cr | -51.40 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 56.0% | 69.3% | 68.7% | 70.8% |
| Operating Margin % | 42.3% | 43.3% | 40.7% | - | 39.5% | 34.3% | 24.2% | 10.6% |
| Net Margin % | 28.8% | 38.0% | 35.8% | - | 30.9% | 29.0% | 18.7% | 7.9% |
| ROE % | 18.9% | 37.5% | 30.7% | - | 23.7% | 14.6% | 28.7% | 4.6% |
| ROCE % | - | - | - | - | 29.1% | 16.6% | 23.6% | 4.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COHANCE
Cohance Lifesciences Limited (NSE:COHANCE) Analysts Are Reducing Their Forecasts For Next Year - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxNYUszN3dGR3lfWkIwYWJlaVY2aXRmdTBtMTlHSDNpUHF6Tm03RjVUbVdIMldiVDg0RmFmSk93Z1pFb3pQT2p3NmViLU5TblZuS1ZDaDA2WWx4bUJ1RG1FRHNpRERzQUxHaWtrWEd4cDRvS0dJUGhxZWotalNScUt5aEhwcElrOVAycE1pTF…
Why Cohance Lifesciences Share Price is Rising - Equitymaster
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPR2dSUTJTNlFJU3FzNkgtcVh1QTA1UTB3YVJ6UG1JNWZqd1A0OURrUTR3c3d5Y1czY3lDWGM3QWs1UUJsaWdnekxqUjZTTEl6TDloRE1aVVptcC1jREZpWU96cWVTdWhfSm9fRGM1WEZfLTZMc3ZBWHVoallQRVpHTHd1QnozR1VLVDMydX…
Cohance shares decline 2% as company CFO resigns - Moneycontrol.com
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQSERDYWV4dklxS2NMeTlNVXF1aWRSc2d3SkNpMHBuZWJtNVIwMHpXX1BOaXRIR190d3dUbUg2blNjZnN1anpSamF1dy1YSFp0d1dPYjl0clJRWWIwVE1SeldUZHl5SlMxcllMWl9weFJsSUVJT1BLWUp6LXRHRkFTdlk5MUNBcFE2QnF6OU…
Cohance Lifesciences shares slip 7% after Jefferies cuts target price, downgrades on weak Q4 - The Economic Times
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxQZjhLLTNZSjdhSGdOX0VGZjVKb2w0R3MzdWtIbTNlaGwwaHRZYXZhbElzMjlLdl9obzkxYjktYTNCVXowUnJUUVlsMlFXbDhqbWtvQUh6N0NPZF8tdVF4UURKU2x2ZGhZRXhpTV9scVdMYmloN3FqTDBSOXlfQkdPOGdLN1RiaEx4em02Vz…
This Pharma Stock Has Rallied 40% In Two Days — Here's Why - NDTV Profit
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNMURMS3ZmR0RITEhmMWQ4ZFc3Szc2dlNfektMeXJzMG9jWmJRVjl1VWxUdzRYaTFhRmtWY1NFdjN1OUJfMVpoaDk3UGQybjROc2xjMUhDV3c5WVIyckdyRGRzQVlFdnBqMVgtSElXOUMxMkZLQVFSS2JSclMwT2xBelJWREtQeFRycThaM1…
Cohance Lifesciences hits 20% upper circuit: Why the stock rising today? - India Today
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxNRlkxc1hQSGdaZnhPb3pmZFVEYkpPanRqUmpWRUo3d3RZRF9ja21RVHFiTzNDZzhzVnFxR29rN2gtUnVZbU0zSU5Db003RERtR1paRXRpMG52TDNyUlBTbTVOMFBDWERIcVRaRFlpTHNpRDMzNjNwVnhlbTVsdlg4NDFYMWxZcF9FT2hHST…
COHANCE — Frequently Asked Questions
What is the current share price of COHANCE LIFESCIENCES LTD (COHANCE)?
As of 2026-07-15 09:52 IST, COHANCE LIFESCIENCES LTD (COHANCE) trades at ₹439.20 on NSE. Its 52-week range is ₹279.90 to ₹1,097.00.
What is the market capitalisation of COHANCE?
COHANCE LIFESCIENCES LTD (COHANCE) has a market capitalisation of ₹16,802.35 Cr on NSE.
What is the P/E ratio of COHANCE?
COHANCE trades at a trailing price-to-earnings (P/E) ratio of 93.85. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.41.
What is the return on equity (ROE) of COHANCE?
COHANCE has a return on equity (ROE) of 4.58%. Its return on capital employed (ROCE) is 4.81%.
Is COHANCE a good stock to buy?
This page provides a data-driven analysis of COHANCE LIFESCIENCES LTD (COHANCE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.